Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough

American Journal of Hypertension

Volumn 13, Issue 2, 2000, Pages 214-218

  Tanser, P H ^a   Campbell, L M ^b   Carranza, J ^c   Karrash, J ^d   Toutouzas, P ^e   Watts, R ^f  

^a ST JOSEPH S HOSPITAL   (Canada)

^b Southbank Surgery   (United Kingdom)

^c HOSPITAL GENERAL DR MIGUEL SILVA   (Mexico)

^d Peninsula Medical Centre   (Australia)

^e HIPPOKRATION HOSPITAL   (Greece)

^f Investigator Clinic   (Australia)

Author keywords

Candesartan cilexetil; Cough; Enalapril; Hypertension; Placebo; Quality of life

Indexed keywords

CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; COUGH; DOUBLE-BLIND METHOD; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTORS, ANGIOTENSIN; SAFETY; TETRAZOLES; TREATMENT OUTCOME;

EID: 0034005673     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(99)00165-X     Document Type: Article

References (13)

1. Fletcher A.E., Palmer A.J., Bulpitt C.J., et al. Cough with angiotensin converting enzyme inhibitors how much of a problem? J Hypertens. 12:(suppl 2):1994;S43-S47.
2. Tomlinson B., Young R.P., Chan J.C.N., et al. Pharmacoepidemiology of ACE inhibitor-induced cough. Drug Saf. 16:1997;150-151.
3. Yeo W.W., Foster G., Ramsey L. Prevalence of persistent cough during long term enalapril treatment controlled study versus nifedipine . Q J Med. 293:1991;763-770.
4. Semple P.F. Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors. J Hypertens. 13:(suppl 3):1995;S17-S21.
5. Tan SA, Berk LS, Tan LG: Increased tachykinins substance P and neurokinin A, not bradykinin, cause the ACE inhibitor induced cough. (abstract). J Am Coll Cardiol 1997;29 (suppl A):41A.
6. 1 receptor. Eur J Pharmacol. 319:1997;137-146.
7. Hübner R., Högemann A.M., Sunzel M., Riddell J.G. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens. 11:(suppl 2):1997;S19-S25.
8. Fletcher A.E., Bulpitt C.J., Hawkins C.M., et al. Quality of life on antihypertensive therapy a randomised double-blind controlled trial of captopril and atenolol . J Hypertens. 8:1990;463-466.
9. Lacourcière Y., Brunner H., Irwin R., et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens. 12:1994;1387-1393.
10. Dahlöf C., Dimenäs E., Olofsson B. Documentation of an instrument for assessment of subjective CNS-related symptoms during cardiovascular pharmacotherapy. Cardiovasc Drugs Ther. 3:1989;919-927.
11. Arakawa K., Ogihara T., Iimura O., et al. Evaluation of clinical usefulness of TCV-116 (candesartan cilexetil) in patients with essential hypertension. A double-blind, parallel group comparison study using enalapril maleate as control drug. J Clin Ther Med. 12:1996;2613-2661.
12. McInnes G.T., Istad H., Keinänen-Kiukaanniemi S., van Mierlo H.F. Combination of candesartan cilexetil/hydrochlorothiazide 8/12.5 mg has a similar antihypertensive effect and is better tolerated than lisinopril/hydrochlorothiazide 10/12.5 mg. (abstract) Am J Hypertens. 11:1998;109A.
13. Benz J., Oshrain C., Henry D., Avery C., Chiang Y.T., Gatlin M. Valsartan, a new angiotensin II receptor antagonist a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide . J Clin Pharmacol. 37:1997;101-107.